Certara, Inc. $CERT Stake Raised by Roubaix Capital LLC

Roubaix Capital LLC raised its stake in shares of Certara, Inc. (NASDAQ:CERT) by 83.5% during the third quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 519,776 shares of the company’s stock after buying an additional 236,568 shares during the quarter. Certara comprises about 3.0% of Roubaix Capital LLC’s investment portfolio, making the stock its 8th biggest position. Roubaix Capital LLC’s holdings in Certara were worth $6,352,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently made changes to their positions in the stock. Wasatch Advisors LP lifted its position in shares of Certara by 45.7% in the second quarter. Wasatch Advisors LP now owns 13,532,882 shares of the company’s stock valued at $158,335,000 after acquiring an additional 4,244,230 shares in the last quarter. Marshall Wace LLP raised its stake in Certara by 1,430.6% in the 2nd quarter. Marshall Wace LLP now owns 1,512,343 shares of the company’s stock valued at $17,694,000 after purchasing an additional 1,413,538 shares during the last quarter. Ameriprise Financial Inc. raised its stake in Certara by 27.1% in the 2nd quarter. Ameriprise Financial Inc. now owns 5,460,630 shares of the company’s stock valued at $63,889,000 after purchasing an additional 1,165,064 shares during the last quarter. Fort Washington Investment Advisors Inc. OH purchased a new position in Certara in the 3rd quarter valued at about $11,899,000. Finally, Mackenzie Financial Corp boosted its stake in shares of Certara by 47.7% during the 2nd quarter. Mackenzie Financial Corp now owns 2,648,549 shares of the company’s stock worth $30,988,000 after purchasing an additional 855,222 shares during the last quarter. 73.96% of the stock is owned by institutional investors and hedge funds.

Certara Trading Down 0.4%

CERT opened at $7.05 on Tuesday. The firm’s 50 day moving average is $8.32 and its 200-day moving average is $9.85. Certara, Inc. has a 52-week low of $6.04 and a 52-week high of $15.38. The company has a quick ratio of 2.05, a current ratio of 2.05 and a debt-to-equity ratio of 0.27. The firm has a market capitalization of $1.12 billion, a P/E ratio of -705.00 and a beta of 1.47.

Certara (NASDAQ:CERT) last released its quarterly earnings results on Thursday, February 26th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). Certara had a positive return on equity of 4.20% and a negative net margin of 0.38%.The firm had revenue of $103.65 million for the quarter, compared to analysts’ expectations of $103.23 million. During the same period last year, the firm earned $0.15 EPS. The business’s quarterly revenue was up 3.2% on a year-over-year basis. Certara has set its FY 2026 guidance at 0.440-0.480 EPS. Analysts expect that Certara, Inc. will post 0.28 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities analysts recently issued reports on CERT shares. BMO Capital Markets assumed coverage on shares of Certara in a research note on Thursday, November 13th. They set a “market perform” rating and a $9.00 price objective on the stock. TD Cowen reissued a “buy” rating on shares of Certara in a research note on Thursday. Leerink Partners restated an “outperform” rating and set a $10.00 price objective on shares of Certara in a report on Thursday. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of Certara in a research report on Monday, December 29th. Finally, Morgan Stanley reduced their target price on Certara from $16.00 to $12.00 and set an “equal weight” rating on the stock in a research report on Thursday, December 18th. One equities research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $11.10.

Certara Profile

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.